Phase III CheckMate 77T Study Podcast

Podcast | English | 2024 | 48 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase III CheckMate 77T study. Perioperative therapy has improved outcomes in patients with resectable NSCLC and is emerging as best practice, but there is nuance to the delivery of this therapy.

Podcast Host:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Tina Cascone, MD, Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Shun Lu, MD, Chief, Shanghai Chest Hospital, Shanghai Lung Cancer Center, Professor at Shanghai Jiaotong University, Shanghai, China